Vector therapies for malignant glioma: shifting the clinical paradigm

Bibliography

• Surawicz TS, McCarthy BJ, Kupelian V, et al. Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990 – 1994. Neuro Oncol 1999;1(1):14-25
   PubMedGoogle Scholar
• Ekstrand AJ, James CD, Cavenee WK, et al. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 1991;51(8):2164-72
   PubMed Web of Science ®Google Scholar
• Bruner JM, Saya H, Moser RP. Immunocytochemical detection of p53 in human gliomas. Mod Pathol 1991;4(5):671-4
   PubMed Web of Science ®Google Scholar
• Frankel RH, Bayona W, Koslow M, Newcomb EW. p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency. Cancer Res 1992;52(6):1427-33
   PubMed Web of Science ®Google Scholar
• Nozaki M, Tada M, Kobayashi H, et al. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression. Neuro Oncol 1999;1(2):124-37
   PubMedGoogle Scholar
• Burns KL, Ueki K, Jhung SL, et al. Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas. J Neuropathol Exp Neurol 1998;57(2):122-30
   PubMed Web of Science ®Google Scholar
• Henson JW, Schnitker BL, Correa KM, et al. The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann Neurol 1994;36(5):714-21
   PubMed Web of Science ®Google Scholar
• Ueki K, Ono Y, Henson JW, et al. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 1996;56(1):150-3
   PubMed Web of Science ®Google Scholar
• He J, Olson JJ, James CD. Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res 1995;55(21):4833-6
   PubMed Web of Science ®Google Scholar
• Ichimura K, Schmidt EE, Goike HM, Collins VP. Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 1996;13(5):1065-72
   PubMed Web of Science ®Google Scholar
• Schmidt EE, Ichimura K, Reifenberger G, Collins VP. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994;54(24):6321-4
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-96
   PubMed Web of Science ®Google Scholar
• Rainov NG, Ren H. Clinical trials with retrovirus mediated gene therapy – what have we learned? J Neurooncol 2003;65(3):227-36
   PubMed Web of Science ®Google Scholar
• Barzon L, Zanusso M, Colombo F, Palu G. Clinical trials of gene therapy, virotherapy, and immunotherapy for malignant gliomas. Cancer Gene Ther 2006;13(6):539-54
   PubMed Web of Science ®Google Scholar
• Chiocca EA, Aghi M, Fulci G. Viral therapy for glioblastoma. Cancer J 2003;9(3):167-79
   PubMed Web of Science ®Google Scholar
• Moolten FL, Vonderhaar BK, Mroz PJ. Transduction of the herpes thymidine kinase gene into premalignant murine mammary epithelial cells renders subsequent breast cancers responsive to ganciclovir therapy. Hum Gene Ther 1996;7(10):1197-204
   PubMed Web of Science ®Google Scholar
• Ishii-Morita H, Agbaria R, Mullen CA, et al. Mechanism of ‘bystander effect’ killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther 1997;4(3):244-51
   PubMed Web of Science ®Google Scholar
• Touraine RL, Ishii-Morita H, Ramsey WJ, Blaese RM. The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication. Gene Ther 1998;5(12):1705-11
   PubMed Web of Science ®Google Scholar
• Long Z, Lu P, Grooms T, et al. Molecular evaluation of biopsy and autopsy specimens from patients receiving in vivo retroviral gene therapy. Hum Gene Ther 1999;10(5):733-40
   PubMed Web of Science ®Google Scholar
• Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000;11(17):2389-401
   PubMed Web of Science ®Google Scholar
• Colombo F, Barzon L, Franchin E, et al. Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. Cancer Gene Ther 2005;12(10):835-48
   PubMed Web of Science ®Google Scholar
• Rainov NG, Kramm CM, Aboody-Guterman K, et al. Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm. Cancer Gene Ther 1996;3(2):99-106
   PubMed Web of Science ®Google Scholar
• Mapara KY, Stevenson CB, Thompson RC, Ehtesham M. Stem cells as vehicles for the treatment of brain cancer. Neurosurg Clin North Am 2007;18(1):71-80, ix
   PubMed Web of Science ®Google Scholar
• Yip S, Sabetrasekh R, Sidman RL, Snyder EY. Neural stem cells as novel cancer therapeutic vehicles. Eur J Cancer 2006;42(9):1298-308
   PubMed Web of Science ®Google Scholar
• Ikeda K, Ichikawa T, Wakimoto H, et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 1999;5(8):881-7
   PubMed Web of Science ®Google Scholar
• Flax JD, Aurora S, Yang C, et al. Engraftable human neural stem cells respond to developmental cues, replace neurons, and express foreign genes. Nat Biotechnol 1998;16(11):1033-9
   PubMed Web of Science ®Google Scholar
• Kim SU. Human neural stem cells genetically modified for brain repair in neurological disorders. Neuropathology 2004;24(3):159-71
   PubMed Web of Science ®Google Scholar
• Lindvall O, Kokaia Z. Recovery and rehabilitation in stroke: stem cells. Stroke 2004;35(11 Suppl 1):2691-4
   PubMed Web of Science ®Google Scholar
• Martinez-Serrano A, Rubio FJ, Navarro B, et al. Human neural stem and progenitor cells: in vitro and in vivo properties, and potential for gene therapy and cell replacement in the CNS. Curr Gene Ther 2001;1(3):279-99
   PubMedGoogle Scholar
• Ourednik J, Ourednik V, Lynch WP, et al. Neural stem cells display an inherent mechanism for rescuing dysfunctional neurons. Nat Biotechnol 2002;20(11):1103-10
   PubMed Web of Science ®Google Scholar
• Brown AB, Yang W, Schmidt NO, et al. Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin. Hum Gene Ther 2003;14(18):1777-85
   PubMed Web of Science ®Google Scholar
• Benedetti S, Pirola B, Pollo B, et al. Gene therapy of experimental brain tumors using neural progenitor cells. Nat Med 2000;6(4):447-50
   PubMed Web of Science ®Google Scholar
• Ehtesham M, Sarangi A, Valadez JG, et al. Ligand-dependent activation of the hedgehog pathway in glioma progenitor cells. Oncogene 2007;26(39):5752-61
   PubMed Web of Science ®Google Scholar
• Kim SK, Kim SU, Park IH, et al. Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression. Clin Cancer Res 2006;12(18):5550-6
   PubMed Web of Science ®Google Scholar
• Shimato S, Natsume A, Takeuchi H, et al. Human neural stem cells target and deliver therapeutic gene to experimental leptomeningeal medulloblastoma. Gene Ther 2007;14(15):1132-42
   PubMed Web of Science ®Google Scholar
• Li S, Tokuyama T, Yamamoto J, et al. Potent bystander effect in suicide gene therapy using neural stem cells transduced with herpes simplex virus thymidine kinase gene. Oncology 2005;69(6):503-8
   PubMed Web of Science ®Google Scholar
• Annabi B, Naud E, Lee YT, et al. Vascular progenitors derived from murine bone marrow stromal cells are regulated by fibroblast growth factor and are avidly recruited by vascularizing tumors. J Cell Biochem 2004;91(6):1146-58
   PubMed Web of Science ®Google Scholar
• Birnbaum T, Roider J, Schankin CJ, et al. Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. J Neurooncol 2007;83(3):241-7
   PubMed Web of Science ®Google Scholar
• Nakamizo A, Marini F, Amano T, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005;65(8):3307-18
   PubMed Web of Science ®Google Scholar
• Schichor C, Birnbaum T, Etminan N, et al. Vascular endothelial growth factor A contributes to glioma-induced migration of human marrow stromal cells (hMSC). Exp Neurol 2006;199(2):301-10
   PubMed Web of Science ®Google Scholar
• Nakamura K, Inaba M, Sugiura K, et al. Enhancement of allogeneic hematopoietic stem cell engraftment and prevention of GVHD by intra-bone marrow bone marrow transplantation plus donor lymphocyte infusion. Stem Cells 2004;22(2):125-34
   PubMed Web of Science ®Google Scholar
• Miletic H, Fischer Y, Litwak S, et al. Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expressing a suicide gene. Mol Ther 2007;15(7):1373-81
   PubMed Web of Science ®Google Scholar
• Fischer YH, Miletic H, Giroglou T, et al. A retroviral packaging cell line for pseudotype vectors based on glioma-infiltrating progenitor cells. J Gene Med 2007;9(5):335-44
   PubMed Web of Science ®Google Scholar
• Shah AC, Benos D, Gillespie GY, Markert JM. Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. J Neurooncol 2003;65(3):203-26
   PubMed Web of Science ®Google Scholar
• Burton EA, Fink DJ, Glorioso JC. Gene delivery using herpes simplex virus vectors. DNA Cell Biol 2002;21(12):915-36
   PubMed Web of Science ®Google Scholar
• Taylor TJ, Brockman MA, McNamee EE, Knipe DM. Herpes simplex virus. Front Biosci 2002;7:d752-64
   PubMed Web of Science ®Google Scholar
• Campadelli-Fiume G, Cocchi F, Menotti L, Lopez M. The novel receptors that mediate the entry of herpes simplex viruses and animal alphaherpesviruses into cells. Rev Med Virol 2000;10(5):305-19
   PubMed Web of Science ®Google Scholar
• Montgomery RI, Warner MS, Lum BJ, Spear PG. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 1996;87(3):427-36
   PubMed Web of Science ®Google Scholar
• Spear MA, Sun F, Eling DJ, et al. Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation. Cancer Gene Ther 2000;7(7):1051-9
   PubMed Web of Science ®Google Scholar
• Batterson W, Furlong D, Roizman B. Molecular genetics of herpes simplex virus. VIII. Further characterization of a temperature-sensitive mutant defective in release of viral DNA and in other stages of the viral reproductive cycle. J Virol 1983;45(1):397-407
   PubMed Web of Science ®Google Scholar
• Batterson W, Roizman B. Characterization of the herpes simplex virion-associated factor responsible for the induction of alpha genes. J Virol 1983;46(2):371-7
   PubMed Web of Science ®Google Scholar
• Braun E, Zimmerman T, Hur TB, et al. Neurotropism of herpes simplex virus type 1 in brain organ cultures. J Gen Virol 2006;87(Pt 10):2827-37
   PubMed Web of Science ®Google Scholar
• Jacobs A, Breakefield XO, Fraefel C. HSV-1-based vectors for gene therapy of neurological diseases and brain tumors. Part II. Vector systems and applications. Neoplasia 1999;1(5):402-16
   PubMedGoogle Scholar
• Chiocca EA, Abbed KM, Tatter S, et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 2004;10(5):958-66
   PubMed Web of Science ®Google Scholar
• Immonen A, Vapalahti M, Tyynela K, et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther 2004;10(5):967-72
   PubMed Web of Science ®Google Scholar
• Lang FF, Bruner JM, Fuller GN, et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 2003;21(13):2508-18
   PubMed Web of Science ®Google Scholar
• Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000;7(10):867-74
   PubMed Web of Science ®Google Scholar
• Sandmair AM, Loimas S, Puranen P, et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 2000;11(16):2197-205
   PubMed Web of Science ®Google Scholar
• Trask TW, Trask RP, Aguilar-Cordova E, et al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 2000;1(2):195-203
   PubMed Web of Science ®Google Scholar
• Harrow S, Papanastassiou V, Harland J, et al. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther 2004;11(22):1648-58
   PubMed Web of Science ®Google Scholar
• Yew PR, Berk AJ. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature 1992;357(6373):82-5
   PubMed Web of Science ®Google Scholar
• Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005;5(12):965-76
   PubMed Web of Science ®Google Scholar
• Farassati F, Lee PW. Ras signalling pathway: a gateway for HSV-1 infection. Sci World J 2003;3:533-5
   Google Scholar
• Farassati F, Yang AD, Lee PW. Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 2001;3(8):745-50
   PubMed Web of Science ®Google Scholar
• Mineta T, Tabuchi K, Martuza RL. Gene therapy for brain tumors: experimental treatment of malignant brain tumors using recombinant herpes simplex virus type 1 (series 7). No Shinkei Geka 1995;23(4):285-92
   PubMedGoogle Scholar
• Hunter WD, Martuza RL, Feigenbaum F, et al. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J Virol 1999;73(8):6319-26
   PubMed Web of Science ®Google Scholar
• Sundaresan P, Hunter WD, Martuza RL, Rabkin SD. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice. J Virol 2000;748:3832-41
   Google Scholar
• Yazaki T, Manz HJ, Rabkin SD, Martuza RL. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res 1995;55(21):4752-6
   PubMed Web of Science ®Google Scholar
• Kanai R, Tomita H, Shinoda A, et al. Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of gamma34.5-mediated virulence. Gene Ther 2006;13(2):106-16
   PubMed Web of Science ®Google Scholar
• Sonabend AM, Ulasov IV, Lesniak MS. Conditionally replicative adenoviral vectors for malignant glioma. Rev Med Virol 2006;16(2):99-115
   PubMed Web of Science ®Google Scholar
• Ulasov IV, Zhu ZB, Tyler MA, et al. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther 2007;18(7):589-602
   PubMed Web of Science ®Google Scholar
• Kajiwara Y, Yamasaki F, Hama S, et al. Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer 2003;97(4):1077-83
   PubMed Web of Science ®Google Scholar
• Chakravarti A, Noll E, Black PM, et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 2002;20(4):1063-8
   PubMed Web of Science ®Google Scholar
• Chakravarti A, Zhai GG, Zhang M, et al. Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 2004;23(45):7494-506
   PubMed Web of Science ®Google Scholar
• Yamada Y, Kuroiwa T, Nakagawa T, et al. Transcriptional expression of survivin and its splice variants in brain tumors in humans. J Neurosurg 2003;99(4):738-45
   PubMed Web of Science ®Google Scholar
• Kambara H, Okano H, Chiocca EA, Saeki Y. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 2005;65(7):2832-9
   PubMed Web of Science ®Google Scholar
• Dahlstrand J, Collins VP, Lendahl U. Expression of the class VI intermediate filament nestin in human central nervous system tumors. Cancer Res 1992;52(19):5334-41
   PubMed Web of Science ®Google Scholar
• Sonabend AM, Ulasov IV, Han Y, Lesniak MS. Oncolytic adenoviral therapy for glioblastoma multiforme. Neurosurg Focus 2006;20(4):E19
   PubMedGoogle Scholar
• Ulasov IV, Tyler MA, Zheng S, et al. CD46 represents a target for adenoviral gene therapy of malignant glioma. Hum Gene Ther 2006;17(5):556-64
   PubMed Web of Science ®Google Scholar
• Tyler MA, Ulasov IV, Borovjagin A, et al. Enhanced transduction of malignant glioma with a double targeted Ad5/3-RGD fiber-modified adenovirus. Mol Cancer Ther 2006;5(9):2408-16
   PubMed Web of Science ®Google Scholar
• Qiao D, Meyer K, Mundhenke C, et al. Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 signaling in brain endothelial cells. Specific role for glypican-1 in glioma angiogenesis. J Biol Chem 2003;278(18):16045-53
   PubMed Web of Science ®Google Scholar
• Zheng S, Ulasov IV, Han Y, et al. Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma. J Gene Med 2007;9(3):151-60
   PubMed Web of Science ®Google Scholar
• Yu L, Shimozato O, Li Q, et al. Adenovirus type 5 substituted with type 11 or 35 fiber structure increases its infectivity to human cells enabling dual gene transfer in CD46-dependent and -independent manners. Anticancer Res 2007;27(4B):2311-6
   PubMed Web of Science ®Google Scholar
• Skog J, Edlund K, Bergenheim AT, Wadell G. Adenoviruses 16 and CV23 efficiently transduce human low-passage brain tumor and cancer stem cells. Mol Ther 2007
   PubMedGoogle Scholar
• Hoffmann D, Heim A, Nettelbeck DM, et al. Evaluation of twenty human adenoviral types and one infectivity-enhanced adenovirus for the therapy of soft tissue sarcoma. Hum Gene Ther 2007;18(1):51-62
   PubMed Web of Science ®Google Scholar
• Brouwer E, Havenga MJ, Ophorst O, et al. Human adenovirus type 35 vector for gene therapy of brain cancer: improved transduction and bypass of pre-existing anti-vector immunity in cancer patients. Cancer Gene Ther 2007;14(2):211-9
   PubMed Web of Science ®Google Scholar
• Hoffmann D, Meyer B, Wildner O. Improved glioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses. J Gene Med 2007;9(9):764-78
   PubMed Web of Science ®Google Scholar
• Hoffman RM. Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenovirus in an orthotopic model of advanced lung cancer. Cancer 2007;109(6):1213; author reply 4
   PubMed Web of Science ®Google Scholar
• Zhou G, Ye GJ, Debinski W, Roizman B. Engineered herpes simplex virus 1 is dependent on IL13Ralpha 2 receptor for cell entry and independent of glycoprotein D receptor interaction. Proc Natl Acad Sci USA 2002;99(23):15124-9
   PubMed Web of Science ®Google Scholar
• Kamiyama H, Zhou G, Roizman B. Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor. Gene Ther 2006;13(7):621-9
   PubMed Web of Science ®Google Scholar
• Gondi CS, Lakka SS, Yanamandra N, et al. Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas. Cancer Res 2004;64(12):4069-77
   PubMed Web of Science ®Google Scholar
• Gondi CS, Lakka SS, Yanamandra N, et al. Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis. Oncogene 2003;22(38):5967-75
   PubMed Web of Science ®Google Scholar
• Gondi CS, Lakka SS, Dinh DH, et al. Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice. Clin Cancer Res 2007;13(14):4051-60
   PubMed Web of Science ®Google Scholar
• Mohanam S, Sawaya RE, Yamamoto M, et al. Proteolysis and invasiveness of brain tumors: role of urokinase-type plasminogen activator receptor. J Neurooncol 1994;22(2):153-60
   PubMed Web of Science ®Google Scholar
• Gondi CS, Lakka SS, Dinh DH, et al. RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene 2004;23(52):8486-96
   PubMed Web of Science ®Google Scholar
• Rustamzadeh E, Li C, Doumbia S, et al. Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme. J Neurooncol 2003;65(1):63-75
   PubMed Web of Science ®Google Scholar
• Debinski W, Slagle B, Gibo DM, et al. Expression of a restrictive receptor for interleukin 13 is associated with glial transformation. J Neurooncol 2000;48(2):103-11
   PubMed Web of Science ®Google Scholar
• Joshi BH, Plautz GE, Puri RK. Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res 2000;60(5):1168-72
   PubMed Web of Science ®Google Scholar
• Debinski W, Gibo DM. Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen. Mol Med 2000;6(5):440-9
   PubMed Web of Science ®Google Scholar
• Friedman A, Tian JP, Fulci G, et al. Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. Cancer Res 2006;66(4):2314-9
   PubMed Web of Science ®Google Scholar
• Fulci G, Breymann L, Gianni D, et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci USA 2006;103(34):12873-8
   PubMed Web of Science ®Google Scholar
• Fulci G, Dmitrieva N, Gianni D, et al. Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res 2007;67(19):9398-406
   PubMed Web of Science ®Google Scholar
• Kurozumi K, Hardcastle J, Thakur R, et al. Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 2007;99(23):1768-81
   PubMed Web of Science ®Google Scholar
• Lamfers ML, Fulci G, Gianni D, et al. Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Mol Ther 2006;14(6):779-88
   PubMed Web of Science ®Google Scholar
• Kristian Raty J, Liimatainen T, Unelma Kaikkonen M, et al. Non-invasive imaging in gene therapy. Mol Ther 2007;15(9):1579-86
   PubMed Web of Science ®Google Scholar
• Anderson SA, Glod J, Arbab AS, et al. Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. Blood 2005;105(1):420-5
   PubMed Web of Science ®Google Scholar
• Chen W. Clinical applications of PET in brain tumors. J Nucl Med 2007;48(9):1468-81
   PubMed Web of Science ®Google Scholar
• Jacobs AH, Rueger MA, Winkeler A, et al. Imaging-guided gene therapy of experimental gliomas. Cancer Res 2007;67(4):1706-15
   PubMed Web of Science ®Google Scholar
• Tang Y, Shah K, Messerli SM, et al. In vivo tracking of neural progenitor cell migration to glioblastomas. Hum Gene Ther 2003;14(13):1247-54
   PubMed Web of Science ®Google Scholar
• Alonso MM, Cascallo M, Gomez-Manzano C, et al. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo. Cancer Res 2007;67(17):8255-63
   PubMed Web of Science ®Google Scholar
• Alonso MM, Gomez-Manzano C, Jiang H, et al. Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo. Cancer Gene Ther 2007;14(8):756-61
   PubMed Web of Science ®Google Scholar
• Lamfers ML, Grill J, Dirven CM, et al. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res 2002;62(20):5736-42
   PubMed Web of Science ®Google Scholar
• Advani SJ, Mezhir JJ, Roizman B, Weichselbaum RR. ReVOLT: radiation-enhanced viral oncolytic therapy. Int J Radiat Oncol Biol Phys 2006;66(3):637-46
   PubMed Web of Science ®Google Scholar
• Zachos T, Diggs A, Weisbrode S, et al. Mesenchymal stem cell-mediated gene delivery of bone morphogenetic protein-2 in an articular fracture model. Mol Ther 2007;15(8):1543-50
   PubMed Web of Science ®Google Scholar
• Xin H, Kanehira M, Mizuguchi H, et al. Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells. Stem Cells 2007;25(7):1618-26
   PubMed Web of Science ®Google Scholar
• Pereboeva L, Komarova S, Mikheeva G, et al. Approaches to utilize mesenchymal progenitor cells as cellular vehicles. Stem Cells 2003;21(4):389-404
   PubMed Web of Science ®Google Scholar
• Stoff-Khalili MA, Rivera AA, Mathis JM, et al. Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat 2007;105(2):157-67
   PubMed Web of Science ®Google Scholar
• Sonabend AM, Ulasov IV, Tyler MA, et al. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 2008 [Epub ahead of print]
   PubMedGoogle Scholar
• Shah K, Weissleder R. Molecular optical imaging: applications leading to the development of present day therapeutics. NeuroRx 2005;2(2):215-25
   PubMedGoogle Scholar
• Isacson O, Breakefield XO. Benefits and risks of hosting animal cells in the human brain. Nat Med 1997;3(9):964-9
   PubMed Web of Science ®Google Scholar
• Aboody KS, Brown A, Rainov NG, et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA 2000;97(23):12846-51
   PubMed Web of Science ®Google Scholar